Dasatinib
- Generic Name
- Dasatinib
- Brand Names
- Sprycel
- Drug Type
- Small Molecule
- Chemical Formula
- C22H26ClN7O2S
- CAS Number
- 302962-49-8
- Unique Ingredient Identifier
- X78UG0A0RN
- Background
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias. Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeri...
- Indication
Dasatinib is indicated for the treatment of newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib, and adults with Philadelphia chromosome-posi...
- Associated Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 204
- Registration Number
- NCT02013648
- Locations
- 🇦🇹
Hanuschkrankenhaus, Wien, Austria
🇦🇹Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇦🇹Universitätsklinik der PMU, Salzburg, Austria
A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT02011945
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦QEII Health Sciences Centre-VG Site, Halifax, Nova Scotia, Canada
🇩🇪Campus Virchow Klinikum Der Charite, Berlin, Germany
Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT01990196
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)
- Conditions
- Interventions
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Versailles Hospital
- Target Recruit Count
- 289
- Registration Number
- NCT01916785
- Locations
- 🇨🇦
Hôpital Charles LeMoyne, Greenfield Park, Canada
🇫🇷Hopital MORVAN, Brest, France
🇨🇦Hôpital Maisonneuve-Rosemont, Montréal, Canada
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- Kanto CML Study Group
- Target Recruit Count
- 100
- Registration Number
- NCT01887561
- Locations
- 🇯🇵
National Disaster Medical Center, Tachikawa city, Tokyo, Japan
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01876953
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Walter J. Storkus
- Target Recruit Count
- 15
- Registration Number
- NCT01876212
- Locations
- 🇺🇸
Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase
- Conditions
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- Poitiers University Hospital
- Registration Number
- NCT01872442
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 84
- Registration Number
- NCT01850004
- Locations
- 🇮🇹
Local Institution - 0025, Catania, Italy
🇺🇸Local Institution - 0013, Chicago, Illinois, United States
🇺🇸Local Institution - 0006, Duarte, California, United States
Study of Dasatinib, Androgen Deprivation Therapy and Radiation
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Brown University
- Registration Number
- NCT01826838
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.